55 results about "Antiplatelets drugs" patented technology

A slide fastener bioabsorbable stent is applied as a cardiovascular system stent or a lumen stent in the disease of cardiovascular or narrow lumen. The slide fastener bioabsorbable stent includes a snap fastener stent, an edge slide fastener stent, a middle slide fastener stent, and a double fastener stent. The slide fastener bioabsorbable stent has good degradability and biocompatibility, and is more suitably used as a pediatric vascular stent, with which no late-onset stent thromboses after implanted, and thus it is not necessary to long-term take antiplatelet drugs and the subsequent surgical operation may not be affected. Also, it has a strong support, and thus can be widely used as a cardiovascular system stent or a lumen stent in the disease of cardiovascular or narrow lumen. The slide fastener bioabsorbable stent has simple production and convenient drug carrying, which can be used as a carrier of medicine or gene treatment. The stent can be matched with a delivery system, hence the difficulty of the surgery operation is reduced. Many animal experiments show that slide fastener bioabsorbable stent has high success ratio when being used, and has apparent curative effect and good clinical application prospect.

This invention is directed to methods and compositions which impede the development and progression of diseases associated with subclinical inflammation. Subclinical inflammation is commonly associated with atherosclerotic cardiovascular disease, coronary disease or cerebrovascular disease. The methods and compositions of the invention are also particularly suited to providing therapy for subclinical inflammation in diabetic and prediabetic patients. Methods of the invention comprise administration of DHA alone and in combination with antiplatelet drugs.

The invention relates to a kit for detecting an antiplatelet drug in blood plasma through an ultra-high performance liquid chromatography-tandem mass spectrometry technology. The pretreatment processis simple, the cost is low, the sensitivity is high, the specificity is high, separation and detection of the antiplatelet drug are completed within 5 min, the accuracy and precision basically meet the requirements, the method can be used for quantitative analysis of the clinical antiplatelet drug, and a reliable detection method is provided for monitoring the treatment concentration of the clinical antiplatelet drug.

The invention provides a method for realizing platelet patterning by polyphenols on material surface. According to the method, a polyphenol and metal ion mixed solution is prepared under chelation between the polyphenols and metal ions and is added dropwise to a seal surface with a micro-pattern, a patterned seal made of the polyphenol material is obtained and finally used for performing micro-contact printing on a target material, and the patterned polyphenol material surface is obtained. After the patterned polyphenol material surface makes contact with platelets, the platelets selectively adhere to areas not covered with the polyphenol material, so that patterning regulation of the platelets is realized. Hydrophilic polymers or bioactive proteins need not to be introduced, and the method has the characteristics of being low in cost and simple and convenient to operate. The prepared platelet patterned surface is expected to be applied to fields such as platelet adhesion detection, antiplatelet drug therapy and evaluation and the like.

The invention relates to the technical field of medical examination, and specially relates to a method for simultaneous determining concentrations of ticagrelor and active metabolites and endogenous adenosine thereof in human plasma by liquid chromatography-mass spectrometry. The concentrations of ticagrelor, active metabolites of ticagrelor and endogenous adenosine in human plasma are simultaneously determined by adopting a liquid chromatography-mass spectrometry technology. The method comprises the following steps: A, simultaneously determining the concentrations of ticagrelor, active metabolites of ticagrelor and endogenous adenosine in human plasma; B, all the samples to be detected can be subjected to peak determination under the same chromatographic and mass spectrometric conditions;and C, simultaneously extracting to-be-detected substances with different polarities in the sample. The method has the advantages that the adenosine concentration change in the blood plasma in the body of the patient and the relationship between the adenosine concentration change and the concentration of the ticagrelor and the active metabolite thereof in the blood plasma after the antiplatelet drug ticagrelor is taken can be accurately, simply, conveniently and quickly evaluated. In addition, pretreatment and chromatographic and mass spectrometric conditions are optimized, so that the determination method is simple, quick and sensitive to operate, high in specificity and good in repeatability.

The invention belongs to the technical field of drug application, relates to a new use of a tumor vascular disrupting agent DMXAA, and in particular relates to the use of the tumor vascular disrupting agent DMXAA in preparation of antiplatelet and antithrombotic drugs, wherein the tumor vascular disrupting agent DMXAA has the structure represented by the formula (I). Through in-vitro, ex-vivo and in-vivo tests of the DMXAA, results show that a DMXAA antiplatelet mechanism is different from that of known antiplatelet drugs such as aspirin, clopidogrel, prasugrel, ticagrelor, cilostazol and fibrinogen receptor antagonists, and the DMXAA simultaneously has dual activities of TXA2 generation inhibition and TXA2 receptor antagonism; and the experimental results indicate that the DMXAA can be used for the preparation of the effective and safe antiplatelet and antithrombotic drugs, and is used for prevention and treatment of arterial thrombotic diseases, such as coronary heart disease, apoplexy, peripheral vascular disease and the like.

The invention belongs to the technical field of biology, and provides a special primer for detecting SNP sites of drug-resistance related genes for anticoagulant and antiplatelet medication. The special primer comprises a primer group 1 and a primer group 2, wherein the primer group 1 is a specific PCR primer composed of 15 pairs of primers, and the primer group 2 is a single base extension primercomposed of 15 primers. The invention further provides a reparation for detecting the SNP sites of drug-resistance related genes for anticoagulant and antiplatelet medication, and a method for detecting the SNP sites of the drug-resistance related genes for anticoagulant and antiplatelet medication. By adopting the special primer provided by the invention, the detection time can be greatly shortened, the cost is saved, and the special primer has a very high application value for guiding precise medication of six clinically common anticoagulant and antiplatelet drugs, and is suitable for popularization and application.

The invention discloses an aspirin resistance-related P2Y1 gene polymorphic site and an application. Antiplatelet drugs (particularly aspirin) play a crucial role in the prevention of ischemic stroke; however, current investigation result indicates that many ischemic stroke patients even taking the antiplatelet drug still suffer relapse of stoke, and the phenomenon is called antiplatelet drug resistance. The applicant defines an aspirin resistance-related P2Y1 gene polymorphic site: P2Y1 (A745G) and designs a primer for detecting the site polymorphism; and the primer can be used for preparing a kit for screening aspirin resistant patients so as to select antiplatelet drugs for the ischemic stroke patients and reduce the aspirin resistance and stoke relapse.

The invention belongs to the technical field of antiplatelet drugs and provides thiomorpholine-containing pyrrole derivatives and pharmaceutically acceptable salts thereof. The thiomorpholine-containing pyrrole derivatives have a general structural formula I. In the general structural formula I, m and R are defined in the patent specification. The invention relates to a preparation method of the thiomorpholine-containing pyrrole derivatives, discloses a drug composition containing the thiomorpholine-containing pyrrole derivatives or their pharmaceutically acceptable salts as active ingredients, and also discloses a use of the thiomorpholine-containing pyrrole derivatives and their pharmaceutically acceptable salts in antiplatelet drugs.

The invention relates to an application of evodiamine in preparation of antiplatelet drugs. The antiplatelet effect is resisting collagen-induced platelet aggregation or resisting thrombin-induced platelet blood clot retraction. An optical turbidimetry detection result shows that the sensitivity is high, the evodiamine has a remarkable inhibition effect on collagen-induced human platelet aggregation and thrombin-induced platelet blood clot retraction, the evodiamine is not limited to inhibition of collagen-induced platelet aggregation, can be used for exploring influences of the evodiamine andother platelet activators (collagen, arachidonic acid, ADP, epinephrine, restomycin and the like) on effects and related functions of platelets, and can also be used for monitoring existing antiplatelet treatment.

The invention discloses compounds with antithrombotic effects with the structure of formula I and pharmaceutically acceptable salts thereof. According to the compound, R can be hydrogen, methyl, ethyl, propyl, isopropyl, nitro, cyano, halogen and trifluoromethyl. The invention also discloses a method for preparing the compounds, a pharmaceutical composition by taking the compounds and the pharmaceutically acceptable salts as active ingredients, and application of serving as antiplatelet drugs, particularly for preparation of medicines for preventing or treating the coronary syndrome, myocardial infarction, myocardial ischemia and other cardiovascular and cerebrovascular diseases caused by platelet aggregation.

The invention discloses an aspirin resistance-related GPIIIa gene polymorphic site and an application. An antiplatelet drug (particularly aspirin) plays a crucial role in the prevention of ischemic stroke; however, current investigation results indicate that many ischemic stroke patients taking the antiplatelet drug still suffer relapse of stroke even, and the phenomenon is called antiplatelet drug resistance. The applicant defines an aspirin resistance-related GPIIIa gene polymorphic site GPIIIa (A1166C) and designs a primer for detecting the site polymorphism for the site, wherein the primer can be used for preparing a kit for screening aspirin resistant patients so as to select an antiplatelet drug for ischemic stroke patients and reduce the aspirin resistance and stroke relapse.

The present invention relates to the application of miRNA in regulating the expression level of Gelsolin and its application in antiplatelet therapy, and the miRNA is miR‑124. It also relates to a method for screening potential anti-platelet therapeutic drugs by screening agents that regulate the above-mentioned miRNA in platelets. Screening experiments showed that ligustrazine, panax notoginseng saponins and aspirin could regulate the level of miR‑124 in platelet cells, thus playing a role in antiplatelet therapy.